Xiangbei Welman Pharmaceutical Co., Ltd.

Welman Pharmaceutical is located in Liuyang Economic and Technological Development Zone, with a registered capital of 365.925 million yuan and an area of 300 mu. It is a large pharmaceutical company integrating science, industry and trade, with continuous innovation and R&D capabilities, focusing on anti-drug-resistant and anti-superbug antibiotic compound preparations, mainly Class 1 innovative drugs. It has the largest R&D, production and sales in South China of penicillin and cephalosporin antibiotic APIs and anti-drug-resistant preparations. It has key layouts in novel drug delivery routes for psychiatric, male sexual dysfunction, gastrointestinal protection, anti-tumor, cardiovascular, and antidepressant drugs. Since its establishment, the company has always adhered to the development philosophy of "self-reliance and courage to innovate". It is one of the first batch of national high-tech enterprises, a Hunan Provincial Enterprise Technology Center, a Hunan Provincial "specialized, refined, distinctive and innovative" little giant, and a *green factory. Since entering the park, it has paid a cumulative total of 1.6 billion yuan in taxes and provided employment for more than a thousand people. It is currently in the IPO period.
The company attaches great importance to innovation and R&D. It has 3 R&D institutions: Xiangbei New Drug Research Institute, Guangzhou New Drug Research Institute and Nanjing New Drug Research Institute. It currently has 150 R&D personnel, including 1 academician, 5 professors, 8 doctoral degree holders, and 31 master's degree holders, among whom 2 are returnee doctoral degree holders. Focusing on improving the innovative technological content of products and enhancing their core competitiveness, the investment in research and development has increased year by year. The company's technology strategy stipulates that no less than 3% of annual sales revenue shall be allocated each year as basic expenditure for scientific research. In 2022, the company carried out R&D on 70 projects, with a cumulative investment of 80.51 million yuan, accounting for 12.40% of total annual sales. In 2023, it carried out R&D on nearly 80 projects, with an investment of more than 80 million yuan. Sufficient and guaranteed R&D funding has promoted the competitive level of products, strengthened the company's core competitiveness, improved its own R&D capabilities and independent innovation level, and laid a solid foundation for the development of innovative technologies and new products.
At present, it has 3 national Class 1 new drug products, including the nationally exclusive Class 1 new drug anti-drug-resistant compound cefotaxime sodium and sulbactam sodium for injection and ceftriaxone sodium and sulbactam sodium for injection, developed in cooperation with experts and academicians such as Academician Li Lanjuan and Academician Wang Guangji; 12 national new drug certificates and 66 drug approval numbers; 151 domestic and foreign patent applications, including 48 authorized domestic invention patents and 11 authorized international patents; and 6 "National Major Science and Technology Projects for New Drug Innovation" of the Ministry of Science and Technology. According to a Thomson Reuters database search, Welman ranks second in the world, after Pfizer, in the number of innovative β-lactam anti-drug-resistant antibiotics and compound antibiotic varieties developed.
To build a complete industrial chain from APIs to preparations, starting in 2022, the company invested more than 1 billion yuan to build the Welman New Drug R&D and Production Base Construction Project in Liuyang Economic and Technological Development Zone, covering an area of 101 mu, with a total construction area of 34,625 square meters. It mainly produces the nationally exclusive Great Drug for PLA combat readiness and Betel Nut Companion, which can effectively cure oral ulcers, oral fibrosis and oral cancer caused by betel nut (which can effectively guarantee and maintain Hunan's 100-billion consumer betel nut product industry_), as well as β-lactamase inhibitor sterile APIs, penicillin sterile APIs, and the world's